Objective biomarkers or symptom scores for the classification of fibromyalgia syndrome?

Current Rheumatology Reviews

Volumn 8, Issue 4, 2012, Pages 307-317

  Staud, Roland ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Biomarker; Central sensitization; Chronic pain; Fibromyalgia; Nociception

Indexed keywords

ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DISEASE CLASSIFICATION; FATIGUE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; HYPERALGESIA; MUSCULOSKELETAL PAIN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RIGIDITY;

EID: 84875311878     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339712805077113     Document Type: Article

References (204)

1. Yunus MB. Central Sensitivity Syndromes: A New Paradigm and Group Nosology for Fibromyalgia and Overlapping Conditions, and the Related Issue of Disease versus Illness. Semin Arthritis Rheum 2008; 37: 339-52.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
3. Friedberg F, Sohl S, Schmeizer B. Publication trends in chronic fatigue syndrome: comparisons with fibromyalgia and fatigue: 1995-2004. J Psychosom Res 2007; 63: 143-6.
4. Lindell L, Bergman S, Petersson IF, Jacobsson LTH, Herrstrom P. Prevalence of fibromyalgia and chronic widespread pain. Scandinavian Journal of Primary Health Care 2000; 18: 149-53.
5. Croft P. The epidemiology of chronic widespread pain. J Musculoskelet Pain 2002; 10: 191-9.
6. Rohrbeck J, Jordan K, Croft P. The frequency and characteristics of chronic widespread pain in general practice: a case-control study. Br J Gen Pract 2007; 57: 109-15.
7. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62: 600-10.
8. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders 2007; 8: 1-11.
9. Henriksson CM. Longterm effects of fibromyalgia on everyday life. A study of 56 patients. Scand J Rheumatol 1994; 23: 36-41.
10. Hudson JI, Goldenberg DL, Pope HG, Jr., Keck PE, Jr., Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992; 92: 363-7.
11. Soderberg S, Lundman B, Norberg A. The meaning of fatigue and tiredness as narrated by women with fibromyalgia and healthy women. J ClinNurs 2002; 11: 247-55.
12. Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995; 22: 151-6.
13. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 1407-17.
14. Price DD, Patel R, Robinson ME, Staud R. Characteristics of electronic visual analogue and numeric scales for ratings of experimental pain in healthy subjects and fibromyalgia patients. Pain 2008; 140: 158-66.
15. Staud R, Robinson ME, Weyl EE, Price DD. Pain Variability in Fibromyalgia Is Related to Activity and Rest: Role of Peripheral Tissue Impulse Input. J Pain 2010; 11: 1376-83.
16. Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci 2006; 1069: 109-17.
17. Crofford LJ. The relationship of fibromyalgia to neuropathic pain syndromes. J Rheumatol Suppl 2005; 75: 41-5.
18. Gerwin RD. A review of myofascial pain and fibromyalgia - factors that promote their persistence. Acupuncture in Medicine 2005; 23: 121-34.
19. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999; 106: 534-43.
20. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6 - A pilot study in fibromyalgia. Arthritis Rheum 2000; 43: 872-80.
21. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593-601.
22. Bradley LA, Alarcon GS, Sotolongo A, et al. Cerebrospinal fluid (CSF) levels of substance P (SP) are abnormal in patients with fibromyalgia (FM) regardless of traumatic or insidious pain onset. Arthritis Rheum 1998; 41: S212.
23. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-6.
24. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 2000; 29: 8-12.
25. Giesecke T, Gracely RH, Grant MAB, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004; 50: 613-23.
26. O'neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Generalized deep-tissue hyperalgesia in patients with chronic low-back pain. Eur J Pain 2007; 11: 415-20.
27. Arroyo JF, Cohen ML. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993; 20: 1925-31.
28. Berglund B, Harju EL, Kosek E, Lindblom U. Quantitative and qualitative perceptual analysis of cold dysesthesia and hyperalgesia in fibromyalgia. Pain 2002; 96: 177-87.
29. Simms RW, Goldenberg DL, Felson DT, Mason JH. Tenderness in 75 anatomic sites.Distinguishing fibromyalgia patients from controls. Arthritis Rheum 1988; 31: 182-7.
30. Jensen K, Andersen HO, Olesen J, Lindblom U. Pressure-pain threshold in human temporal region. Evaluation of a new pressure algometer.Pain 1986; 25: 313-23.
31. Ohrbach R, Gale EN. Pressure pain thresholds in normal muscles: reliability, measurement effects, and topographic differences. Pain 1989; 37: 257-63.
32. Ohrbach R, Gale EN. Pressure pain thresholds, clinical assessment, and differential diagnosis: reliability and validity in patients with myogenic pain. Pain 1989; 39: 157-69.
33. Kosek E, Ekholm J, Nordemar R. A comparison of pressure pain thresholds in different tissues and body regions.Long-term reliability of pressure algometry in healthy volunteers. Scand J Rehabil Med 1993; 25: 117-24.
34. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48: 1420-9.
35. Hurtig IM, Raak RI, Kendall SA, Gerdle B, Wahren LK. Quantitative sensory testing in fibromyalgia patients and in healthy subjects: Identification of subgroups. Clin J Pain 2001; 17: 316-22.
36. White KP, Harth M, Speechley M, Ostbye T. A general population study of fibromyalgia tender points in noninstitutionalized adults with chronic widespread pain. J Rheumatol 2000; 27: 2677-82.
37. Vierck CJ, Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain 2006; 124: 242-63.
38. Woolf CJ, Doubell TP. The pathophysiology of chronic pain-- increased sensitivity to low threshold A beta-fibre inputs. Curr Opin Neurobiol 1994; 4: 525-34.
39. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 1769-72.
40. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999; 26: 1564-9.
41. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353-9.
42. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994; 36: 244-6.
43. Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010; 40: 109-26.
44. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. CurrOpinMolTher 2010; 12: 94-106.
45. Xian CJ, Zhou XF. Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative. Nat ClinPract Rheum 2009; 5: 92-8.
46. Fu KY, Light AR, Maixner W. Long-lasting inflammation and long-term hyperalgesia after subcutaneous formalin injection into the rat hindpaw. J Pain 2001; 2: 2-11.
47. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001; 40: 743-9.
48. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003; 30: 146-50.
49. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991; 104: 765-7.
50. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46: 1333-43.
51. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003; 105: 403-13.
52. Emery EC, Young GT, Berrocoso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science 2011; 333: 1462-6.
53. Arendt-Nielsen L, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract Res ClinRheumatol 2007; 21: 465-80.
54. Dubner R. Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. In Proceedings of Vth World Congress on Pain.Pain Research and Clinical Management. Edited by Bond M, Charlton E, Woolf CJ. Amsterdam: Elsevier; 1991: 263-276.
55. Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. ProgNeurobiol 1992; 38: 397-421.
56. Fock S, Mense S. Excitatory effects of 5-hydroxytryptamine, histamine and potassium ions on muscular group IV afferent units: a comparison with bradykinin. Brain Res 1976; 105: 459-69.
57. Griesbacher T, Lembeck F. Effect of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E2 release, nociceptor stimulation and contraction of the iris sphincter muscle in the rabbit. Br J Pharmacol 1987; 92: 333-40.
58. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 1993; 54: 241-89.
59. Mense S, Hoheisel U, Reinert A. The possible role of substance P in eliciting and modulating deep somatic pain. Prog Brain Res 1996; 110: 125-35.
60. Schaible HG, Grubb BD. Afferent and spinal mechanisms of joint pain. Pain 1993; 55: 5-54.
61. Barber LA, Vasko MR. Activation of protein kinase C augments peptide release from rat sensory neurons. J Neurochem 1996; 67: 72-80.
62. Khasar SG, Ouseph AK, Chou B, Ho T, Green PG, Levine JD. Is there more than one prostaglandin E receptor subtype mediating hyperalgesia in the rat hindpaw? Neuroscience 1995; 64: 1161-5.
63. Abbott FV, Hong Y, Blier P. Persisting sensitization of the behavioural response to formalin- induced injury in the rat through activation of serotonin2A receptors. Neuroscience 1997; 77: 575-84.
64. Sann H, Pierau FK. Efferent functions of C-fiber nociceptors. Z Rheumatol 1998; 57: 8-13.
65. Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994; 37: 794-800.
66. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scan J Rheumatol 1986; 15: 165-73.
67. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001; 24: 37-46.
68. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998; 41: 406-13.
69. Bengtsson A, Henriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol 1986; 15: 1-6.
70. Wall PD, Woolf CJ. Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J PhysiolLond 1984; 356: 443-58.
71. De Stefano R, Selvi E, Villanova M, et al. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000; 27: 2906-10.
72. Kosek E, Ekholm J, Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain 1995; 63: 335-9.
73. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997; 40: 446-52.
74. Neumann L, Zeldets V, Bolotin A, Buskila D. Outcome of posttraumatic fibromyalgia: A 3-year follow-up of 78 cases of cervical spine injuries. Semin Arthritis Rheum 2003; 32: 320-5.
75. Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino MA. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 2011; 15: 61-9.
76. Bengtsson M, Bengtsson A, Jorfeldt L. Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain 1989; 39: 171-80.
77. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992; 51: 175-94.
78. Lautenbacher S, Fillingim RB. Pathophysiology of Pain Perception. 2004.
79. Staud R, Robinson ME, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain 2003; 105: 215-22.
80. Staud R, Koo E, Robinson ME, Price DD. Spatial summation of mechanically evoked muscle pain and painful aftersensations in normal subject and fibromyalgia patients. Pain 2007; 130: 177-87.
81. Ge HY, Wang Y, Fernandez-de-las-Penas C, Graven-Nielsen T, Danneskiold-Samsoe B, Arendt-Nielsen L. Reproduction of overall spontaneous pain pattern by manual stimulation of active myofascial trigger points in fibromyalgia patients. Arthritis Res Ther 2011; 13: R48.
82. Banic B, Petersen-Felix S, Andersen OK, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004; 107: 7-15.
83. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Evidence, mechanisms, and clinical implications of central hypersensitivity in chronic pain after whiplash injury. Clin J Pain 2004; 20: 469-76.
84. Kamper SJ, Maher CG, Hush JM, Pedler A, Sterling M. Relationship Between Pressure Pain Thresholds and Pain Ratings in Patients With Whiplash-associated Disorders. Clin J Pain 2011; 27: 495-501.
85. Hansson P, Ekblom A, Lindblom U, Marchettini P. Does acute intraoral pain alter cutaneous sensibility? J Neurol Neurosurg Psychiatry 1988; 51: 1032-6.
86. Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 1995; 63: 341-51.
87. Lapossy E, Maleitzke R, Hrycaj P, Mennet W, Muller W. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 1995; 24:29-33.
88. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Giani C, Zbinden AM, Radanov BP. Central hypersensitivity in chronic pain after whiplash injury. Clin J Pain 2001; 17: 306-15.
89. Okifuji A, Turk DC. Stress and psychophysiological dysregulation in patients with Fibromyalgia syndrome. Appl Psychophysiol Biofeedback 2002; 27: 129-41.
90. Bajaj P, Bajaj P, Madsen H, Moller M, Arendt-Nielsen L. Antenatal women with or without pelvic pain can be characterized by generalized or segmental hypoalgesia in late pregnancy. J Pain 2002; 3: 451-60.
91. Ushida T, Willis WD. Changes in dorsal horn neuronal responses in an experimental wrist contracture model. J OrthopSci 2001; 6: 46-52.
92. Hoheisel U, Koch K, Mense S. Functional reorganization in the rat dorsal horn during an experimental myositis. Pain 1994; 59: 111-8.
93. Price DD, McHaffie JG, Larson MA. Spatial summation of heatinduced pain: influence of stimulus area and spatial separation of stimuli on perceived pain sensation intensity and unpleasantness. J Neurophysiol 1989; 62: 1270-9.
94. Staud R, Vierck CJ, Robinson ME, Price DD. Spatial summation of heat pain within and across dermatomes in fibromyalgia patients and pain-free subjects. Pain 2004; 111: 342-50.
95. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005; 114: 295-302.
96. Herren-Gerber R, Weiss S, Arendt-Nielsen L, et al. Modulation of central hypersensitivity by nociceptive input in chronic pain after whiplash injury. Pain Med 2004; 5: 366-76.
97. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105: 223-30.
98. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia--are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997; 24: 1615-21.
99. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 1998; 25: 152-5.
100. Graven-Nielsen T, Aspegren KS, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000; 85: 483-91.
101. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (windup) in patients with fibromyalgia syndrome. Pain 2001; 91: 165-75.
102. Granot M, Buskila D, Granovsky Y, Sprecher E, Neumann L, Yarnitsky D. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clinical Neurophysiology 2001; 112: 1881-7.
103. Lorenz J, Grasedyck K, Bromm B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. ElectroencephalogrClinNeurophysiol 1996; 100: 165-8.
104. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189-96.
105. Mendell LM. Physiological properties of unmyelinated fiber projection to the spinal cord. ExpNeurol 1966; 16: 316-32.
106. Price DD. Characteristics of second pain and flexion reflexes indicative of prolonged central summation. ExpNeurol 1972; 37: 371-87.
107. Price DD, Hu JW, Dubner R, Gracely RH. Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 1977; 3: 57-68.
108. Price DD, Hayes RL, Ruda M, Dubner R. Spatial and temporal transformations of input to spinothalamic tract neurons and their relation to somatic sensations. J Neurophysiol 1978; 41: 933-47.
109. Torebjork HE, Hallin RG. Responses in human A and C fibres to repeated electrical intradermal stimulation. J Neurol Neurosurg Psychiatry 1974; 37: 653-64.
110. Dickenson AH, Sullivan AF. NMDA receptors and central hyperalgesic states. Pain 1991; 46: 344-6.
111. Price DD, Mao J, Mayer DJ. Central neural mechanisms of normal and abnormal pain states. In Pharmacological approaches to the treatment of pain: new concepts and critical issues. Edited by Fields HL, Liebeskind JC. Seattle: I.A.S.P. Press; 1994: 61-84.
112. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain 1999; 79: 75-82.
113. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846-50.
114. Granges G, Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 1993; 36: 642-6.
115. Kong J, Gollub RL, Rosman IS, et al. Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J Neurosci 2006; 26: 381-8.
116. Mason P. Ventromedial medulla: pain modulation and beyond. J Comp Neurol 2005; 493: 2-8.
117. Dubner R, Ren K. Endogenous mechanisms of sensory modulation. Pain 1999; Suppl 6:S45-S53.
118. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain 2002; 100: 1-6.
119. van Wijk G, Veldhuijzen DS. Perspective on Diffuse Noxious Inhibitory Controls as a Model of Endogenous Pain Modulation in Clinical Pain Syndromes. J Pain 2010; 11: 408-19.
120. Edwards RR, Fillingim RB. Effects of age on temporal summation and habituation of thermal pain: clinical relevance in healthy older and younger adults. J Pain 2001; 2: 307-17.
121. Tracey I, Dunckley P. Importance of anti- and pro-nociceptive mechanisms in human disease. Gut 2004; 53: 1553-5.
122. Staud R, Cannon RC, Mauderli AP, Robinson ME, Price DD, Vierck CJ. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 2003; 102: 87-95.
123. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000; 88: 69-78.
124. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267-84.
125. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the NDMA receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal controls. J Pain 2005; 6: 323-32.
126. Arendt-Nielsen L, Mansikka H, Staahl C, et al. A translational study of the effects of ketamine and pregabalin on temporal summation of experimental pain. Reg Anesth Pain Med 2011; 36: 585-91.
127. Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol ExpTher 1999; 289: 1060-6.
128. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends PharmacolSci 2001; 22: 636-42.
129. Sherrington CS, Sowton SC. Observations on reflex responses to single break-shots. J Physiol 1915; 49: 331-48.
130. Bernard C. Leconssur le physiologieet la pathologie du systemenerveaux. Paris: Baillere; 1858.
131. Sillery E, Bittar RG, Robson MD, et al. Connectivity of the human periventricular-periaqueductal gray region. J Neurosurg 2005; 103: 1030-4.
132. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66:355-474.
133. Mayer DJ, Wolfle TL, Akil H, Carder B, Liebeskind JC. Analgesia from electrical stimulation in the brainstem of the rat. Science 1971; 174: 1351-4.
134. Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 1977; 197: 183-6.
135. Mantyh PW. Connections of midbrain periaqueductal gray in the monkey. II. Descending efferent projections. J Neurophysiol 1983; 49: 582-94.
136. Mantyh PW. Connections of midbrain periaqueductal gray in the monkey. I. Ascending efferent projections. J Neurophysiol 1983; 49: 567-81.
137. Swett JE, McMahon SB, Wall PD. Long ascending projections to the midbrain from cells of lamina I and nucleus of the dorsolateral funiculus of the rat spinal cord. J Comp Neurol 1985; 238: 401-16.
138. Roby-Brami A, Bussel B, Willer JC, Le Bars D. An electrophysiological investigation into the pain-relieving effects of heterotopic nociceptive stimuli.Probable involvement of a supraspinal loop. Brain 1987; 110: 508.
139. Bouhassira D, Villanueva L, Bing Z, Le Bars D. Involvement of the subnucleusreticularisdorsalis in diffuse noxious inhibitory controls in the rat. Brain Res 1992; 595: 353-7.
140. Villanueva L, Bouhassira D, Le Bars D. The medullary subnucleusreticularisdorsalis (SRD) as a key link in both the transmission and modulation of pain signals. Pain 1996; 67: 231-40.
141. Desbois C, Villanueva L. The organization of lateral ventromedial thalamic connections in the rat: a link for the distribution of nociceptive signals to widespread cortical regions. Neuroscience 2001; 102: 885-98.
142. Desbois C, Le Bars D, Villanueva L. Organization of cortical projections to the medullary subnucleusreticularisdorsalis: a retrograde and anterograde tracing study in the rat. J Comp Neurol 1999; 410: 178-96.
143. Goffaux P, Redmond WJ, Rainville P, Marchand S. Descending analgesia - When the spine echoes what the brain expects. Pain 2007; 130: 137-43.
144. Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595-601.
145. Shyu BC, Sikes RW, Vogt LJ, Vogt BA. Nociceptive processing by anterior cingulate pyramidal neurons. J Neurophysiol 2010; 103: 3287-301.
146. Neogi T, Felson D, Niu JB, et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ 2009; 339: b2844.
147. Kalichman L, Kim DH, Li L, Guermazi A, Hunter DJ. Computed tomography-evaluated features of spinal degeneration: prevalence, intercorrelation, and association with self-reported low back pain. Spine J 2010; 10: 200-8.
148. Jacobs JW, Rasker JJ, van-der-Heide A, et al. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res 1996; 9: 105-11.
149. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon RL, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002; 99: 49-59.
150. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189-96.
151. Kosek E, Ekholm J. Modulation of pressure pain thresholds during and following isometric contraction. Pain 1995; 61: 481-6.
152. Staud R, Robinson ME, Price DD. Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. Pain 2005; 118: 176-84.
153. King CD, Wong F, Currie T, Mauderli AP, Fillingim RB, Riley JL. Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder. Pain 2009; 143: 172-8.
154. Smith BW, Tooley EM, Montague EQ, Robinson AE, Cosper CJ, Mullins PG. Habituation and sensitization to heat and cold pain in women with fibromyalgia and healthy controls. Pain 2008; 140: 420-8.
155. de Tommaso M, Federici A, Santostasi R, et al. Laser-Evoked Potentials Habituation in Fibromyalgia. J Pain 2011; 12: 116-24.
156. Goffaux P, de Souza JB, Potvin S, Marchand S. Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain 2009; 145: 18-23.
157. Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 2004; 110: 689-96.
158. Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep 2003; 7: 355-61.
159. Staud R, Craggs JG, Perlstein WM, Robinson ME, Price DD. Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. Eur J Pain 2008; 12: 1078-89.
160. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004; 31: 364-78.
161. Kong J, White NS, Kwong KK, et al. Using fMRI to dissociate sensory encoding from cognitive evaluation of heat pain intensity. Hum Brain Mapp 2006; 27: 715-21.
162. Deco G, Jirsa VK, McIntosh AR. Emerging concepts for the dynamical organization of resting-state activity in the brain. Nat Rev Neurosci 2011; 12: 43-56.
163. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van E, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. ProcNatlAcadSci U S A 2005; 102: 9673-8.
164. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. ProcNatlAcadSci U S A 2001; 98: 676-82.
165. Fransson P. Spontaneous low-frequency BOLD signal fluctuations: an fMRI investigation of the resting-state default mode of brain function hypothesis. Hum Brain Mapp 2005; 26: 15-29.
166. Chang C, Glover GH. Time-frequency dynamics of resting-state brain connectivity measured with fMRI. Neuroimage 2010; 50: 81-98.
167. Fox MD, Snyder AZ, Zacks JM, Raichle ME. Coherent spontaneous activity accounts for trial-to-trial variability in human evoked brain responses. Nat Neurosci 2006; 9: 23-5.
168. Fox MD, Corbetta M, Snyder AZ, Vincent JL, Raichle ME. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. ProcNatlAcadSci U S A 2006; 103: 10046-51.
169. Cordes D, Haughton VM, Arfanakis K, et al. Mapping functionally related regions of brain with functional connectivity MR imaging. AJNR Am J Neuroradiol 2000; 21: 1636-44.
170. Hampson M, Peterson BS, Skudlarski P, Gatenby JC, Gore JC. Detection of functional connectivity using temporal correlations in MR images. Hum Brain Mapp 2002; 15: 247-62.
171. Zhang D, Snyder AZ, Fox MD, Sansbury MW, Shimony JS, Raichle ME. Intrinsic functional relations between human cerebral cortex and thalamus. J Neurophysiol 2008; 100: 1740-8.
172. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27: 2349-56.
173. Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting- state networks across healthy subjects. Proc Natl Acad Sci U S A 2006; 103: 13848-53.
174. Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex 2009; 19: 72-8.
175. Napadow V, LaCount L, Park K, As-Sanie S, Clauw DJ, Harris RE. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum 2010; 62: 2545-55.
176. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008; 58: 903-7.
177. Foerster BR, Petrou M, Edden RAE, et al. Reduced insular gammaaminobutyric acid in fibromyalgia. Arthritis Rheum 2012; 64: 579-83.
178. Flor H, Diers M. Sensorimotor training and cortical reorganization. Neurorehabilitation 2009; 25: 19-27.
179. Flor H, Nikolajsen L, Staehelin Jensen T. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006; 7: 873-81.
180. Goebel A. Complex regional pain syndrome in adults. Rheumatology 2011; 50: 1739-50.
181. Robinson ME, Craggs JG, Price DD, Perlstein WM, Staud R. Gray matter volumes of pain-related brain areas are decreased in fibromyalgia syndrome. J Pain 2010; 12: 436-43.
182. Schmidt-Wilcke T, Hierlmeier S, Leinisch E. Altered Regional Brain Morphology in Patients With Chronic Facial Pain. Headache 2010; 50: 1278-85.
183. Burgmer M, Gaubitz M, Konrad C, et al. Decreased Gray Matter Volumes in the Cingulo-Frontal Cortex and the Amygdala in Patients With Fibromyalgia. Psychosom Med 2009; 71: 566-73.
184. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007; 27: 4004-7.
185. Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 2004; 24: 10410-5.
186. Schmidt-Wilcke T, Leinisch E, Ganssbauer S, et al. Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain 2006; 125: 89-97.
187. May A, Apkarian AV. Structural brain changes in patients with chronic back pain. In Fom Acute to Chronic Back Pain: Risk Factors, Mechanisms, and Clinical Implications. Edited by Hasenbring MI, Rusu AC, Turk DC. New York: Oxford University Press; 2012: 105-114.
188. May A. Structural Brain Imaging: A Window into Chronic Pain. Neuroscientist 2011; 17: 209-20.
189. Seminowicz DA, Wideman TH, Naso L, et al. Effective Treatment of Chronic Low Back Pain in Humans Reverses Abnormal Brain Anatomy and Function. Journal of Neuroscience 2011; 31: 7540-50.
190. Gwilym SE, Fillipini N, Douaud G, Carr AJ, Tracey I. Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty; a longitudinal voxel-based-morphometric study. Arthritis Rheum 2010; 62: 2930-40.
191. Wegener ST, Castillo RC, Haythornthwaite J, Mackenzie EJ, Bosse MJ. Psychological distress mediates the effect of pain on function. Pain 2011; 152: 1349-57.
192. Hall AM, Kamper SJ, Maher CG, Latimer J, Ferreira ML, Nicholas MK. Symptoms of depression and stress mediate the effect of pain on disability. Pain 2011; 152: 1044-51.
193. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011; 38: 1113-22.
194. Turk DC. The potential of treatment matching for subgroups of patients with chronic pain - Lumping versus splitting. Clin J Pain 2005; 21: 44-55.
195. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003; 48: 2916-22.
196. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple- dose clinical trial. ClinTher 2008; 30: 1988-2004.
197. Mease PJ, Clauw DJ, Gendreau RM, et al. The Efficacy and Safety of Milnacipran for Treatment of Fibromyalgia. A Randomized, Double-blind, Placebo-controlled Trial. J Rheumatol 2009; 36: 398-409.
198. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Clin J Pain 2009; 25: 461-8.
199. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73.
200. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo controlled trial. Pain 2009; 145: 96-104.
201. Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007; 21: 481-97.
202. Staud R. Evidence for Shared Pain Mechanisms in Osteoarthritis, Low Back Pain, and Fibromyalgia. Curr Rheumatol Rep 2011; 13: 513-20.
203. Staud R. Peripheral pain mechanisms in chronic widespread pain. Best Pract Res Clin Rheumatol 2011; 25: 155-64.
204. Staud R. Brain Imaging in Fibromyalgia Syndrome. Clin Exp Rheumatol 2011; 29: S109-17.